Quantiphi has made a strategic minority investment in Transcell, a leading biotech innovator. This collaboration aims to enhance AI-supported drug discovery and development processes in the life sciences sector. The partnership focuses on reducing animal testing and accelerating preclinical decisions for biotherapeutics and vaccines.
The integration of AI and stem cell technology is expected to improve treatment outcomes and elevate industry standards. Both companies are committed to ethical AI practices, which will facilitate automated bioassay implementation. This investment aligns with Quantiphi's ongoing strategy to enhance customer value through innovative partnerships.
• Quantiphi's investment enhances AI-driven drug discovery and development.
• Collaboration aims to reduce animal testing in pharmaceutical research.
This approach aims to streamline research and development, making it more efficient and effective.
The partnership emphasizes ethical AI to support automated bioassay implementation.
This technology is crucial for accelerating decision-making processes in drug development.
Quantiphi's investment in Transcell reflects its commitment to advancing AI in healthcare.
Transcell aims to improve treatment outcomes through innovative, animal-free testing strategies.
The Wall Street Journal 6month
SiliconANGLE 11month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.